Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP)
2006-002792-41Phase 2Completed
- Sponsor
- FoldRx Pharmaceuticals
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in familial amyloid polyneuropathy (FAP) comparing Fx-1006A (tafamidis) with Placebo (2 arms). Primary endpoints: Disease progression in familial amyloid polyneuropathy and Pharmacodynamic stabilization of V30M transthyretin. Started Sep 2006; status: completed.
02
Drugs
tafamidis
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on 2006-002792-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002792-41.